Clinical inertia: Viewpoints of general practitioners and diabetologists

Diabetes and Metabolism

Volumn 38, Issue SUPPL. 3, 2012, Pages

  Avignon, A ^a,b   Attali, C ^c   Sultan, A ^a   Ferrat, E ^c   Le Breton, J ^c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

Clinical inertia; Diabetologists; General practitioners; Review

Indexed keywords

ANTIDIABETIC AGENT;

ARTICLE; CLINICAL PRACTICE; DIABETOLOGIST; GENERAL PRACTITIONER; GLYCEMIC CONTROL; HUMAN; MEDICAL DECISION MAKING; PHYSICIAN; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; RISK FACTOR;

ATTITUDE OF HEALTH PERSONNEL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRANCE; GENERAL PRACTITIONERS; GUIDELINE ADHERENCE; HUMANS; INTERNAL MEDICINE; MALE; MEDICATION ADHERENCE; PHYSICIAN-PATIENT RELATIONS; PRACTICE GUIDELINES AS TOPIC;

EID: 84860385118     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/S1262-3636(12)71535-5     Document Type: Article

References (30)

1. Bousquet J., Anto J.M., Sterk P.J., Adcock I.M., Chung K.F., Roca J., et al. Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Med 2011, 3:43.
2. Lancet 1998, 352:837-853. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
3. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
4. Conditions NCGC for A and C, NICE. Type 2 diabetes (partially updated by CG87) [Internet]. [Cited 2011 Dec 18]; Available from: . http://www.nice.org.uk/cg66.
5. American Diabetes Association. Standards of Medical Care in Diabetes-2011. Diabetes Care 201030;34(Suppl1):S11-61.
6. InVS. Le diabète. échantillon national témoin représentatif des personnes diabétiques (Entred) 2007-2010 > Résultats épidémiologiques principaux d'Entred-métropole [Internet]. [Cited 2011 Dec 14]; Available from: . http://www.invs.sante.fr/surveillance/diabete/entred_2007_2010/resultats_metropole_principaux.htm.
7. Cramer J.A. A systematic review of adherence with medications for diabetes. Diabetes Care 2004, 27:1218-1224.
8. Wens J., Vermeire E., Royen P.V., Sabbe B., Denekens J. GPs'perspectives of type 2 diabetes patients' adherence to treatment: a qualitative analysis of barriers and solutions. BMC Fam Pract 2005, 6:20.
9. Little P., Everitt H., Williamson I., Warner G., Moore M., Gould C., et al. Preferences of patients for patient centred approach to consultation in primary care: observational study. BMJ 2001, 322:468-472.
10. Cook C.B., Ziemer D.C., El-Kebbi I.M., Gallina D.L., Dunbar V.G., Ernst K.L., et al. Diabetes in urban African-Americans. XVI. Overcoming clinical inertia improves glycemic control in patients with type 2 diabetes. Diabetes Care 1999, 22:1494-1500.
11. Phillips L.S., Branch W.T., Cook C.B., Doyle J.P., El-Kebbi I.M., Gallina D.L., et al. Clinical inertia. Ann Intern Med 2001, 135:825-834.
12. Balkau B., Halimi S., Bouée S., Attali C., Avignon A., Vergès B., et al. Type 2 diabetes treatment intensification in General Practice in France: 2008-2009. Diabetes Metab 2011, 37:S1-S7.
13. Donabedian A. The quality of care. How can it be assessed?. JAMA 1988, 260:1743-1748.
14. McDonald C.J. Medical heuristics: the silent adjudicators of clinical practice. Ann Intern Med 1996, 124:56-62.
15. Hemmingsen B., Lund S.S., Gluud C., Vaag A., Almdal T., Hemmingsen C., et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011, 343:d6898.
16. Lacroix A., Assal J.-P. L'éducation thérapeutique des patients: nouvelles approches de la maladie chronique. Maloine 2003, 240.
17. Grant R.W., Wexler D.J., Watson A.J., Lester W.T., Cagliero E., Campbell E.G., et al. How doctors choose medications to treat type 2 diabetes: A national survey of specialists and academic generalists. Diabetes Care 2007, 30:1448-1453.
18. Harris S.B., Kapor J., Lank C.N., Willan A.R., Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician 2010, 56:e418-e424.
19. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370:1706-1713.
20. Graham D.J., Ouellet-Hellstrom R., MaCurdy T.E., Ali F., Sholley C., Worrall C., et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated With rosiglitazone or pioglitazone. JAMA 2010, 304:411-418.
21. Spécialités pharmaceutiques contenant de la pioglitazone - Laboratoire TAKEDA - Retrait - AFSSAPS: Agence française de sécurité sanitaire des produits de santé [Internet]. [Cited 2011 Dec 18]; Available from: . http://www.afssaps.fr/Infos-de-securite/Retraits-de-lots-et-de-produits/Specialites-pharmaceutiques-contenant-de-la-pioglitazone-Laboratoire-TAKEDA-Retrait.
22. Mullard A. Mediator scandal rocks French medical community. Lancet 2011, 377:890-892.
23. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. The Action to Control Cardiovascular Risk in Diabetes study group.
24. Haute Autorité de Santé. Traitement médicamenteux du diabète de type 2: recommandation retirée le 2 mai 2011 [Internet]. [Cited 2011 Dec 18]; Available from: . http://www.has-sante.fr/portail/jcms/c_459270/traitement-medicamenteux-du-diabete-de-type-2-recommandation-retiree-le-2-mai-2011.
25. Parchman M.L., Zeber J.E., Palmer R.F. Participatory decision making, patient activation, medication adherence, and intermediate clinical outcomes in type 2 diabetes: A STARNet study. Ann Fam Med 2010, 8:410-417.
26. Street R.L., Haidet P. How well do doctors know their patients? Factors affecting physician understanding of patients' health beliefs. J Gen Intern Med 2011, 26:21-27.
27. Parchman M.L., Pugh J.A., Romero R.L., Bowers K.W. Competing demands or clinical inertia: the case of elevated glycosylated hemoglobin. Ann Fam Med 2007, 5:196-201.
28. Rodondi N., Peng T., Karter A.J., Bauer D.C., Vittinghoff E., Tang S., et al. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med 2006, 144:475-484.
29. Glasgow R.E., Peeples M., Skovlund S.E. Where is the patient in diabetes performance measures?. Diabetes Care 2008, 31:1046-1050.
30. Phillips L.S., Ziemer D.C., Doyle J.P., Barnes C.S., Kolm P., Branch W.T., et al. An endocrinologist-supported intervention aimed at providers improves diabetes management in a primary care site. Diabetes Care 2005, 28:2352-2360.